BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27328499)

  • 41. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
    Yang XQ; Chen C; Wang FB; Peng CW; Li Y
    Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
    Gao Y; Wang J; Zhou Y; Sheng S; Qian SY; Huo X
    Sci Rep; 2018 Feb; 8(1):2732. PubMed ID: 29426902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma.
    Wang W; Chen XL; Zhao SY; Xu YH; Zhang WH; Liu K; Chen XZ; Yang K; Zhang B; Chen ZX; Chen JP; Zhou ZG; Hu JK
    Oncotarget; 2016 Jun; 7(23):35423-36. PubMed ID: 27097114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic values of normal preoperative serum cancer markers for gastric cancer.
    Feng F; Sun L; Liu Z; Liu S; Zheng G; Xu G; Guo M; Lian X; Fan D; Zhang H
    Oncotarget; 2016 Sep; 7(36):58459-58469. PubMed ID: 27533455
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum levels of CA15-3, AFP, CA19-9 and CEA tumor markers in cancer care and treatment of patients with impaired renal function on hemodialysis.
    Estakhri R; Ghahramanzade A; Vahedi A; Nourazarian A
    Asian Pac J Cancer Prev; 2013; 14(3):1597-9. PubMed ID: 23679242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].
    Pecking AP; Mechelany-Corone C; Pichon MF
    Pathol Biol (Paris); 2000 Nov; 48(9):819-24. PubMed ID: 11141917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
    Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
    Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma.
    Qiu Y; He J; Chen X; Huang P; Hu K; Yan H
    Clin Chim Acta; 2018 May; 480():186-192. PubMed ID: 29438681
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW; Tong KJ; Tam TN; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
    Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
    Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of freeze-thaw cycles on serum measurements of AFP, CEA, CA125 and CA19-9.
    Gao YC; Yuan ZB; Yang YD; Lu HK
    Scand J Clin Lab Invest; 2007; 67(7):741-7. PubMed ID: 17852813
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].
    Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S
    Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
    Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
    Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
    Zhang W; Wang L; Xin Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0358. PubMed ID: 29668586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
    Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
    Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum tumor markers in hemodialysis patients.
    Maoujoud O; El Machtani S; Asseraji M; Atbib Y; Zajjari Y; Taoufik A; Elbouaiti E; Zouhair O; Benyahia M; Tellal S
    Int J Artif Organs; 2014 Feb; 37(2):126-32. PubMed ID: 24619900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.
    Yousef A; Yousef M; Zeineddine MA; More A; Fanaeian M; Chowdhury S; Knafl M; Edelkamp P; Ito I; Gu Y; Pattalachinti V; Naini ZA; Zeineddine FA; Peterson J; Alfaro K; Foo WC; Jin J; Bhutiani N; Higbie V; Scally CP; Kee B; Kopetz S; Goldstein D; Strach M; Williamson A; Aziz O; Barriuso J; Uppal A; White MG; Helmink B; Fournier KF; Raghav KP; Taggart MW; Overman MJ; Shen JP
    JAMA Netw Open; 2024 Feb; 7(2):e240260. PubMed ID: 38416491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.